박세훈 교수
#비뇨의학암
|
학력
2010.02 가천의과학대학교 대학원 의학과 (박사)
2004.02 성균관대학교 의과대학원 의학과 (석사)
1994.02 건국대학교 의과대학 의학과 졸업 (의학사)
2004.02 성균관대학교 의과대학원 의학과 (석사)
1994.02 건국대학교 의과대학 의학과 졸업 (의학사)
경력
2016.04 ~현재 삼성서울병원 혈액종양내과 교수
2010.04 ~ 2016.03 삼성서울병원 혈액종양내과 부교수
2008.03 ~ 2010.03 삼성서울병원 혈액종양내과 조교수
2003.03 ~ 2008.02 가천의과학대학교 길병원 혈액종양내과 조교수
2002.03 ~ 2003.02 삼성서울병원 혈액종양내과 전임의
2002.02 내과 전문의 자격 취득
1998.03 ~ 2002.02 삼성서울병원 내과 전공의 (레지던트) 수료
1997.05 ~ 1998.02 삼성서울병원 인턴과정 수료
2010.04 ~ 2016.03 삼성서울병원 혈액종양내과 부교수
2008.03 ~ 2010.03 삼성서울병원 혈액종양내과 조교수
2003.03 ~ 2008.02 가천의과학대학교 길병원 혈액종양내과 조교수
2002.03 ~ 2003.02 삼성서울병원 혈액종양내과 전임의
2002.02 내과 전문의 자격 취득
1998.03 ~ 2002.02 삼성서울병원 내과 전공의 (레지던트) 수료
1997.05 ~ 1998.02 삼성서울병원 인턴과정 수료
논문
THER ADV MED ONCOL 2020 10.1177/1758835920926796
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J
LANCET 2020 10.1016/S0140-6736(20)30230-0
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Galsky1, MD; Arija, JAA; Bamias, A; Davis, ID; De Santis, M; Kikuchi, E; Garcia-del-Muro, X; De Giorgi, U; Mencinger, M; Izumi, K; Panni, S; Gumus, M; Ozguroglu, M; Kalebasty, AR; Park, SH; Alekseev, B; Schutz, FA; Li, JR; Ye, DW; Vogelzang, NJ; Bernhard, S; Tayama, D; Mariathasan, S; Mecke, A; Thastrom, A; Grande, E
Transl Cancer Res 2020 10.21037/tcr-19-1876
Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
Hong1, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST
Genome Med 2020 10.1186/s13073-020-00741-6
Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient
Lee1, HW; Chung, W; Lee, HO; Jeong, D; Jo, A; Lim, JE; Hong, JH; Nam, DH; Jeong, BC; Park, SH; Joo, KM; Park, WY
PATHOL RES PRACT 2020 10.1016/j.prp.2020.152881
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features
Liu1, XQ; Choi, MG; Kim, K; Kim, KM; Kim, ST; Park, SH; Cristescu, R; Peter, S; Lee, J
INT J MOL SCI 2020 10.3390/ijms21082825
Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
Kim1, H; Lee, SJ; Lee, IK; Min, SC; Sung, HH; Jeong, BC; Lee, J; Park, SH
TARGET ONCOL 2020 10.1007/s11523-020-00706-0
Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study
Byeon1, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
CANCERS 2020 10.3390/cancers12040943
Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer
Yu1, JI; Park, HC; Lee, J; Choi, C; Kang, WK; Park, SH; Kim, ST; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Kim, S; Lim, DH
JAMA-J AM MED ASSOC 2020 10.1001/jama.2020.1707
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial
Tap1, WD; Wagner, AJ; Schoffski, P; Martin-Broto, J; Krarup-Hansen, A; Ganjoo, KN; Yen, CC; Razak, AAR; Spira, A; Kawai, A; Le Cesne, A; Van Tine, BA; Naito, Y; Park, SH; Fedenko, A; Papai, Z; Soldatenkova, V; Shahir, A; Mo, G; Wright, J; Jones, RL
Front Oncol 2020 10.3389/fonc.2020.00314
Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer
Kim1, J; Kim, B; Kang, SY; Heo, YJ; Park, SH; Kim, ST; Kang, WK; Lee, J; Kim, KM
ESMO OPEN 2020 10.1136/esmoopen-2020-000670
Clinical scoring system for the prediction of survival of patients with advanced gastric cancer
Kim1, J; Hong, JY; Kim, ST; Park, SH; Jekal, SY; Choi, JS; Chang, DK; Kang, WK; Seo, SW; Lee, J
PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820
TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer
Hong1, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK
J CLIN ONCOL 2020 10.1200/JCO.19.01638
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Antonarakis1, ES; Piulats, JM; Gross-Goupil, M; Goh, J; Ojamaa, K; Hoimes, CJ; Vaishampayan, U; Berger, R; Sezer, A; Alanko, T; de Wit, R; Li, CD; Omlin, A; Procopio, G; Fukasawa, S; Tabata, KI; Park, SH; Feyerabend, S; Drake, CG; Wu, HY; Qiu, P; Kim, J; Poehlein, C; de Bono, JS
Genome Med 2020 10.1186/s13073-020-0717-8
Comprehensive pharmacogenomic characterization of gastric cancer
Sa1, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J
J ONCOL 2020 10.1155/2020/4659062
Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers
Lee1, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO
외 다수
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J
LANCET 2020 10.1016/S0140-6736(20)30230-0
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Galsky1, MD; Arija, JAA; Bamias, A; Davis, ID; De Santis, M; Kikuchi, E; Garcia-del-Muro, X; De Giorgi, U; Mencinger, M; Izumi, K; Panni, S; Gumus, M; Ozguroglu, M; Kalebasty, AR; Park, SH; Alekseev, B; Schutz, FA; Li, JR; Ye, DW; Vogelzang, NJ; Bernhard, S; Tayama, D; Mariathasan, S; Mecke, A; Thastrom, A; Grande, E
Transl Cancer Res 2020 10.21037/tcr-19-1876
Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
Hong1, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST
Genome Med 2020 10.1186/s13073-020-00741-6
Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient
Lee1, HW; Chung, W; Lee, HO; Jeong, D; Jo, A; Lim, JE; Hong, JH; Nam, DH; Jeong, BC; Park, SH; Joo, KM; Park, WY
PATHOL RES PRACT 2020 10.1016/j.prp.2020.152881
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features
Liu1, XQ; Choi, MG; Kim, K; Kim, KM; Kim, ST; Park, SH; Cristescu, R; Peter, S; Lee, J
INT J MOL SCI 2020 10.3390/ijms21082825
Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
Kim1, H; Lee, SJ; Lee, IK; Min, SC; Sung, HH; Jeong, BC; Lee, J; Park, SH
TARGET ONCOL 2020 10.1007/s11523-020-00706-0
Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study
Byeon1, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
CANCERS 2020 10.3390/cancers12040943
Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer
Yu1, JI; Park, HC; Lee, J; Choi, C; Kang, WK; Park, SH; Kim, ST; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Kim, S; Lim, DH
JAMA-J AM MED ASSOC 2020 10.1001/jama.2020.1707
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial
Tap1, WD; Wagner, AJ; Schoffski, P; Martin-Broto, J; Krarup-Hansen, A; Ganjoo, KN; Yen, CC; Razak, AAR; Spira, A; Kawai, A; Le Cesne, A; Van Tine, BA; Naito, Y; Park, SH; Fedenko, A; Papai, Z; Soldatenkova, V; Shahir, A; Mo, G; Wright, J; Jones, RL
Front Oncol 2020 10.3389/fonc.2020.00314
Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer
Kim1, J; Kim, B; Kang, SY; Heo, YJ; Park, SH; Kim, ST; Kang, WK; Lee, J; Kim, KM
ESMO OPEN 2020 10.1136/esmoopen-2020-000670
Clinical scoring system for the prediction of survival of patients with advanced gastric cancer
Kim1, J; Hong, JY; Kim, ST; Park, SH; Jekal, SY; Choi, JS; Chang, DK; Kang, WK; Seo, SW; Lee, J
PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820
TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer
Hong1, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK
J CLIN ONCOL 2020 10.1200/JCO.19.01638
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Antonarakis1, ES; Piulats, JM; Gross-Goupil, M; Goh, J; Ojamaa, K; Hoimes, CJ; Vaishampayan, U; Berger, R; Sezer, A; Alanko, T; de Wit, R; Li, CD; Omlin, A; Procopio, G; Fukasawa, S; Tabata, KI; Park, SH; Feyerabend, S; Drake, CG; Wu, HY; Qiu, P; Kim, J; Poehlein, C; de Bono, JS
Genome Med 2020 10.1186/s13073-020-0717-8
Comprehensive pharmacogenomic characterization of gastric cancer
Sa1, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J
J ONCOL 2020 10.1155/2020/4659062
Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers
Lee1, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO
외 다수
저서
저서 내용이 없습니다.
보도자료
[건강한 인생] 癌 정복 희망봉을 향하여‥(2) 암 놓치지 않으려면
https://www.hankyung.com/society/article/2009011900181?intype=1
말기암 환자 ‘임상 약’ 사용 쉬워진다
https://news.joins.com/article/3393337
국내 첫 ‘암 전이 지도’ 나왔다
https://www.donga.com/news/article/all/20080403/8563185/1
https://www.hankyung.com/society/article/2009011900181?intype=1
말기암 환자 ‘임상 약’ 사용 쉬워진다
https://news.joins.com/article/3393337
국내 첫 ‘암 전이 지도’ 나왔다
https://www.donga.com/news/article/all/20080403/8563185/1
포스팅
포스팅 내용이 없습니다.
영상자료
영상자료 내용이 없습니다.
발표자료
발표자료 내용이 없습니다.